Regeneron's Phase 2 olatorepatide obesity trial recruiting across five U.S. sites

Regeneron opened one new trial this week for its dual incretin candidate olatorepatide.

• Regeneron Pharmaceuticals is sponsoring a Phase 2, randomized, placebo-controlled study of olatorepatide, a GLP-1/GIP receptor agonist, testing different doses and titration schedules in participants with overweight or obesity who do not have diabetes.¹ The trial is listed as recruiting, with an actual start date of 2026-07-28 and estimated primary completion on 2028-01-21. Enrollment: 360 participants (estimated).¹ Primary outcomes include occurrence and severity of treatment-emergent adverse events, plus percent change in body weight from baseline to week 52.¹ The study is running at five sites, all in the United States.¹